

DAFTAR PUSTAKA

1. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. *J Hepatol.* 2021;74(1):168–84.
2. Siagian TH. Corona Dengan Discourse Network Analysis. *J Kebijakan Kesehat Indones.* 2020;09(02):98–106.
3. Komite Penanganan COVID-19 dan Pemulihan Ekonomi Nasional. Peta Sebaran COVID-19. Komite Penanganan COVID-19 dan Pemulihan Ekonomi Nasional. Peta Sebaran COVID-19.
4. Kemenkes RI. Situasi Terkini Perkembangan Novel Coronavirus (Covid-19).
5. Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS One.* 2021;16(3 March):1–14.
6. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. *Clin Chim Acta.* 2020;508:254–66.
7. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. *Eur J Pharmacol.* 2020;889(October):173644.
8. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Disponible
9. Leaf RK, Al-Samkari H, Brenner SK, Gupta S, Leaf DE. ABO phenotype and death in critically ill patients with COVID-19. *Br J Haematol.* 2020;190(4):e204–8.
10. Wu BB, Gu DZ, Yu JN, Yang J, Wang-Qin S. Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis. *Infect Genet Evol.* 2020;84:104485.
11. Cooling L. Blood groups in infection and host susceptibility. *Clin Microbiol Rev.* 2015;28(3):801–70.
12. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. *Clin Infect Dis.* 2020;2019(Xx Xxxx):1–4.
13. Goel R, Bloch EM, Pirenne F, Al-Riyami AZ, Crowe E, Dau L, et al. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. *Vox Sang.* 2021;116(8):849–61.

14. Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. *Stem Cells Transl Med.* 2020;9(9):1007–22.
15. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol.* 2020;92(4):401–2.
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506.
17. Hasan A, Susanto H, Kasim MF, Nuraini N, Lestari B, Triany D, et al. Superspreading in early transmissions of COVID-19 in Indonesia. *Sci Rep* [Internet]. 2020;10(1):1–5. Available from: <https://doi.org/10.1038/s41598-020-79352-5>
18. World Health Organization. COVID-19 Weekly Epidemiological Update 22. *World Heal Organ.* 2021;(January):1–3.
19. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020;395(10224):565–74.
20. Bárcena M, Oostergetel GT, Bartelink W, Faas FGA, Verkleij A, Rottier PJM, et al. Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirus. *Proc Natl Acad Sci U S A.* 2009;106(2):582–7.
21. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–33.
22. Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. *Turkish J Med Sci.* 2020;50(SI-1):549–56.
23. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J Am Med Assoc.* 2020;324(8):782–93.
24. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol.* 2020;251(3):228–48.

25. Li F, Li W, Farzan M, Harrison SC. Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science* (80-). 2005;309(5742):1864–8.
26. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci.* 2020;63(3):457–60.
27. World Health Organization, Mission China Joint. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO-China Jt Mission Coronavirus Dis 2019. 2020;2019(February):16–24.
28. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med.* 2020;8(4):e20.
29. Gao Y , Ding M, Dong X, Zhang J , Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Vol. 76, *Allergy: European Journal of Allergy and Clinical Immunology.* 2021. 428–455 p.
30. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature.* 2020;584(7821):430–6.
31. South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use during the Pandemic: The Pediatric Perspective. *Hypertension.* 2020;76(1):16–22.
32. Hikmawati I, Setiyabudi R. Hipertensi Dan Diabetes Militus Sebagai Penyakit Penyerta Utama Covid-19 Di Indonesia Hypertension and Diabetes Mellitus As Covid-19 Comorbidities in Indonesia. *Pros Semin Nas Lppm Ump.* 2020;0(0):95–100.
33. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr Clin Res Rev.* 2020;14(4):303–10.
34. Erener S. Diabetes, infection risk and COVID-19. *Mol Metab.* 2020;39:101044.
35. Földi M, Farkas N, Kiss S, Zádori N, Váncsa S, Szakó L, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis. *Obes Rev.* 2020;21(10):1–9.
36. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality

- (Review). *Mol Med Rep.* 2020;22(1):9–19.
37. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol.* 2020;59(1):78–88.
38. Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary disease. *Eur J Clin Invest.* 2020;50(10):0–2.
39. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol.* 2020;5(6):529–30.
40. Phoswa WN, Khaliq OP. Is pregnancy a risk factor of COVID-19? *Eur J Obstet Gynecol Reprod Biol.* 2020;252(2019):605–9.
41. Pringle KG, Tadros MA, Callister RJ, Lumbers ER. The expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: Roles in trophoblast invasion and angiogenesis? *Placenta.* 2011;32(12):956–62.
42. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. *Pedoman Tatalaksana COVID-19.* 2020. 36–37 p.
43. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indones.* 2020;7(1):45.
44. Narang AN. Mekanisme Gangguan Kardiovaskuler pada Covid-19. *Cermin Dunia Kedokt.* 2021;48(1):39–43.
45. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol.* 2020;92(4):424–32.
46. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020;10(2):102–8.
47. Pierrakos. Acute Respiratory Distress Syndrome: Pathophysiology and Therapeutic Options. *J Clin Med Res.* 2012;4(1):7–16.
48. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19.’ *J Infect.* 2020;80(6):607–13.
49. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of covid-19. *Viruses.* 2020;12(4):1–17.
50. Davies PDO. Multi-drug resistant tuberculosis. *CPD Infect.* 2002;3(1):9–12.

51. Lam N, Muravez SN, Boyce RW. A comparison of the Indian Health Service counseling technique with traditional, lecture-style counseling. *J Am Pharm Assoc.* 2015;55(5):503–10.
52. Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. *Virologia J.* 2020;17(1):1–7.
53. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al. Evaluation of the panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19. *J Clin Microbiol.* 2021;59(2):19–21.
54. Chen H, Ai L, Lu H, Li H. Clinical and imaging features of COVID-19. *Radiol Infect Dis.* 2020;7(2):43–50.
55. Jiang Z-Z, He C, Wang D-Q, Shen H-L, Sun J-L, Gan W-N, et al. The Role of Imaging Techniques in Management of COVID-19 in China: From Diagnosis to Monitoring and Follow-Up. *Med Sci Monit Int Med J Exp Clin Res.* 2020 Jul;26:e924582.
56. Yang Y, Li W, Zhang Q, Zhang L, Cheung T, Xiang YT. Mental health services for older adults in China during the COVID-19 outbreak. *The Lancet Psychiatry.* 2020;7(4):e19.
57. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev.* 2020;36(7):1–9.
58. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Vol. 55, *European Respiratory Journal.* 2020. 2000547 p.
59. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc.* 2020;323(11):1061–9.
60. O’Sullivan F, Al-Haddad M. Acute respiratory distress syndrome. *Anaesth Intensive Care Med.* 2013;14(10):472–4.
61. Zhang X, Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. *Postgrad Med J.* 2020;1–5.
62. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical

- determinant of survival in human septic shock. *Crit Care Med.* 2006;34(6):1589–96.
63. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence.* 2014;5(1):4–11.
 64. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. *Nat Rev Dis Prim.* 2016;2(June).
 65. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med.* 2003;31(4):1250–6.
 66. Farhud DD, Yeganeh MZ. A brief history of human blood groups. *Iran J Public Health.* 2013;42(1):1–6.
 67. Uwaezuoke SN, Eze JN, Ayuk AC, Ndu IK. ABO histo-blood group and risk of respiratory atopy in children: a review of published evidence. *Pediatr Heal Med Ther.* 2018;Volume 9:73–9.
 68. Franchini M, Frattini F, Crestani S, Bonfanti C, Lippi G. Von Willebrand factor and cancer: A renewed interest. *Thromb Res.* 2013;131(4):290–2.
 69. Hosoi E. Biological and clinical aspects of ABO blood group system. *J Med Investig.* 2008;55(3–4):174–82.
 70. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. *medRxiv.* 2020;1–18.
 71. Liao Y, Xue L, Gao J, Wu A, Kou X. ABO blood group-associated susceptibility to norovirus infection: A systematic review and meta-analysis. *Infect Genet Evol* 2020;81:104245.
 72. Degarege A, Gebrezgi MT, Beck-Sague CM, Wahlgren M, De Mattos LC, Madhivanan P. Effect of ABO blood group on asymptomatic, uncomplicated and placental *Plasmodium falciparum* infection: Systematic review and meta-analysis. *BMC Infect Dis.* 2019;19(1):1–15.
 73. Jing W, Zhao S, Liu J, Liu M. ABO blood groups and hepatitis B virus infection: A systematic review and meta-analysis. *BMJ Open.* 2020;10(1):1–9.
 74. Chakrani Z, Robinson K, Taye B. Association Between ABO Blood Groups and *Helicobacter pylori* Infection: A Meta-Analysis. *Sci Rep.* 2018;8(1):1–11.
 75. MUNBY DL, WATSON AH. ABO Blood Types and COVID-19- Spurious,

- Anecdotal, or Truly Important Relationships. *Road Passeng Transp Road Goods Transp.* 1978;31–40.
76. Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. *Eur J Prev Cardiol.* 2020;27(13):1436–7.
77. de França NDG, Poli MCC, de Almeida Ramos PG, da Rocha Borsoi CS, Colella R. Titers of ABO antibodies in group O blood donors. *Rev Bras Hematol Hemoter.* 2011;33(4):259–62.
78. Sugiyono. *Metode penelitian kuantitatif, kualitatif, dan R&D.* Bandung:Alfabet; 2021. 81–91 p.
79. Ward SE, O’Sullivan JM, O’Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. *Blood.* 2020;136(25):2864–74.
80. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA - J Am Med Assoc.* 2020;323(16):1574–81.
81. Kalantari H, Haji A, Tabrizi H, Foroohi F. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).
82. Fried, Michael W, *et al.* Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States. *Patient Charact Outcomes 11,721 Patients with COVID19 Hosp Across United States.* 2020;
83. Levi JE, Telles PR, Scrivani H, Campana G. Lack of association between ABO blood groups and susceptibility to SARS-CoV-2 infection. *Vox Sang.* 2021;116(2):251–2.
84. Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between abo and rh blood groups and sars-cov-2 infection or severe covid-19 illness. *Ann Intern Med.* 2021;174(3):308–15.
85. Latz CA, DeCarlo C, Boitano L, Png CYM, Patell R, Conrad MF, et al. Blood type and outcomes in patients with COVID-19. *Ann Hematol.* 2020;99(9):2113–8.
86. Badedi M, Alnami A, Darraj H, Alrajhi A, Mutawwam DA, Somaily M, et al.

Clinical characteristics and ABO blood groups in COVID-19 patients, Saudi Arabia. *Medicine (Baltimore)*. 2021;100(30):e26738.

87. Destylya D. Karakteristik Pasien Covid-19 Di Rumah Sakit Umum Pusat Haji Adam Malik Medan Sumatera Utara. 2021;
88. Khan M, Khan ST. *Epidemiology and Progress So Far*. 2021;1–25.
89. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. *Nat Commun*. 2020;11(1):1–27.
90. Ilpaj SM, Nurwati N. Analisis Pengaruh Tingkat Kematian Akibat Covid-19 Terhadap Kesehatan Mental Masyarakat Di Indonesia. *Focus J Pekerj Sos*. 2020;3(1):16.
91. Mahmud R, Rassel MA, Monayem FB, Sayeed SKJB, Islam MS, Islam MM, et al. Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: A prospective study in the largest COVID-19 dedicated hospital in Bangladesh. *PLoS One*. 2021;16(4 April):1–10.
92. Takagi H. Down the Rabbit-Hole of blood groups and COVID-19. *Br J Haematol*. 2020;190(5):e268–70.
93. Connors J, Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. 2021;

